J. Merritt

发表

Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy.

C. Dinney, L. Pagliaro, J. Slaton, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Decreased monocyte function in patients with Hodgkin's disease

J. A. Merritt, L. Leb, J. Merritt, 1978, Cancer.

Clinical evaluation of adenoviral-mediated p53 gene transfer: review of INGN 201 studies.

J. Roth, C. Logothetis, J. Merritt, 2001, Seminars in oncology.

Modulation of 2',5'-oligoadenylate synthetase in patients treated with alpha-interferon: effects of dose, schedule, and route of administration.

L. A. Ball, E. Borden, K. Sielaff, 1986, Journal of interferon research.

Phase I, pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancer.

A. Tolcher, C. Takimoto, D. V. Von Hoff, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study.

Yuan Zhang, N. Senzer, J. Nemunaitis, 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

Gene therapy for non-small cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 gene replacement.

W. Hong, J. Roth, S. Swisher, 1998, Seminars in oncology.

Active specific immunotherapy of metastatic melanoma with an antiidiotype vaccine: a phase I/II trial of I-Mel-2 plus SAF-m.

S. Groshen, C. Spears, J. Merritt, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Interferons: Biological Response Modification and Pharmacology

B. Edwards, E. Borden, J. Merritt, 1982 .

Phase I trial of interferon-γ (IFN-γ) retroviral vector administered intratumorally to patients with metastatic melanoma

J. Nemunaitis, M. Pike, D. Ando, 1999, Cancer Gene Therapy.

An open label, phase I/II clinical trial to evaluate the safety and biological activity of HIV-IT (V) (HIV-1IIIBenv/rev retroviral vector) in HIV-1-infected subjects.

R. Haubrich, J. McCutchan, J. Merritt, 1995, Human gene therapy.

Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type p53 (Ad-p53)

F. Khuri, W. Hong, J. Roth, 2000, Cancer Gene Therapy.

P53 gene replacement for cancer--interactions with DNA damaging agents.

J. Roth, S. Swisher, R. Komaki, 2001, Acta oncologica.

Gene therapy approaches for the management of non-small cell lung cancer.

J. Roth, S. Swisher, R. Komaki, 2001, Seminars in oncology.

Transient neurologic dysfunction following moderate‐dose methotrexate for undifferentiated lymphoma

J. Brown, A. Benson, J. Lesser, 1984, Cancer.

Evidence That Transfer of Functional p53 Protein Results in Increased Apoptosis in Prostate Cancer

K. Do, C. Wood, T. McDonnell, 2004, Clinical Cancer Research.

Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer.

F. Khuri, W. Hong, J. Roth, 1999, Journal of the National Cancer Institute.

Repeated I ntravesical I nstillations o f a n A denoviral V ector i n Patients W ith L ocally A dvanced B ladder C ancer: A P hase I Study o f p53 Gene T herapy

C. Dinney, L. Pagliaro, J. Slaton, 2003 .

Measurement of 2',5'-oligoadenylate synthetase in patients receiving interferon-alpha.

L. A. Ball, E. Borden, J. Merritt, 1985, Journal of interferon research.

Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients.

Yuan Zhang, R. Ramesh, N. Senzer, 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

Phase 1 trial of oral bropirimine in superficial bladder cancer.

D. Lamm, E. Crawford, R. Flanigan, 1992, The Journal of urology.

Low doses of interferon alpha result in more effective clinical natural killer cell activation.

B. Edwards, E. Borden, R. Fuhlbrigge, 1985, The Journal of clinical investigation.

AugmentedAntiproliferativeEffects of Interferonsat Elevated Temperaturesagainst HumanBladderCarcinomaCell Lines 1

E. Borden, H. Robins, G. Bryan, 2006 .

AugmentedAntiproliferativeEffects of Interferonsat Elevated Temperaturesagainst HumanBladderCarcinomaCell Lines

E. Borden, H. Robins, G. Bryan, 2006 .

Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer.

F. Khuri, J. Roth, J. Lee, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Modulation of 2',5'-oligoadenylate synthetase in patients treated with alpha-interferon: effects of dose, schedule, and route of administration.

L. A. Ball, E. Borden, K. Sielaff, 1986, Journal of interferon research.

Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma.

S. Lippman, W. Hong, J. Roth, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy.

J. Gu, F. Khuri, W. Hong, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

CT Evaluation of Non-small Cell Lung Cancer Treated with Adenoviral p53 Gene Therapy

R. Munden, J. Roth, S. Swisher, 2002 .

Comparison of the biologic effects of two recombinant human interferons alpha (rA and rD) in humans.

K. Simon, L. A. Ball, B. Edwards, 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gene replacement strategies for treating non-small cell lung cancer.

J. Roth, S. Swisher, J. Nemunaitis, 2000, Seminars in radiation oncology.

Bivariate analysis of the p53 pathway to evaluate Ad-p53 gene therapy efficacy.

L. Zumstein, J. Jacobberger, S. Wright, 1999, Cytometry.

Augmented antiproliferative effects of interferons at elevated temperatures against human bladder carcinoma cell lines.

E. Borden, H. Robins, G. Bryan, 1984, Cancer research.

Enhancement of monocyte class I and II histocompatibility antigen expression in man by in vivo beta-interferon.

R. L. Jordan, E. Borden, G. Spear, 1987, Clinical and experimental immunology.

Effects of diethyldithiocarbamate, an inhibitor of interferon antiviral activity, upon human natural killer cells.

B. Edwards, E. Borden, J. Merritt, 1984, Journal of Immunology.

Adenoviral-mediated p53 gene transfer to non-small cell lung cancer through endobronchial injection.

J. Roth, S. Swisher, J. Nemunaitis, 2000, Chest.

2-5A synthetase activity in patients with metastatic carcinoma and its response to interferon treatment.

L. A. Ball, E. Borden, J. Merritt, 1985, Progress in clinical and biological research.

Phase III multicenter randomized clinical trial to evaluate the safety and efficacy of CoFactor/5-fluorouracil/bevacizumab versus leucovorin/5-fluorouracil/bevacizumab as initial treatment for metastatic colorectal carcinoma.

M. Saif, J. Robbins, J. Merritt, 2006, Clinical colorectal cancer.

Phase I trial of interferon-gamma (IFN-gamma) retroviral vector administered intratumorally to patients with metastatic melanoma.

J. Nemunaitis, M. Pike, D. Ando, 1999, Cancer gene therapy.

1007. Safety of Adenoviral Vectors: Results of Clinical Investigations in 445 Cancer Patients Treated with Advexin|[reg]| (Adenoviral p53) Gene Therapy

L. Zumstein, R. Sobol, J. Merritt, 2004 .